Research progress on the mechanisms of Tripterygium wilfordii and its active components on immunoglobulin A nephropathy
- VernacularTitle:雷公藤及其活性成分对免疫球蛋白A肾病的作用机制研究进展
- Author:
Peidong ZHAO
1
;
Yanyan GUO
2
;
Xiangge REN
1
;
Jiawei ZHANG
1
;
Wensheng ZHAI
3
Author Information
1. Henan Children’s Hospital，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450099，China;School of Pediatrics，Henan University of Chinese Medicine，Zhengzhou 450046，China
2. The Fourth Clinical Medical College of Xinjiang Medical University，Urumqi 830054，China
3. Henan Children’s Hospital，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450099，China
- Publication Type:Journal Article
- Keywords:
Tripterygium wilfordii;
immunoglobulin A nephropathy;
active ingredients;
mechanism of action
- From:
China Pharmacy
2025;36(21):2742-2746
- CountryChina
- Language:Chinese
-
Abstract:
Immunoglobulin A nephropathy （IgAN） is a common primary glomerular disease and a frequent cause of chronic renal failure. Tripterygium wilfordii is a traditional Chinese herbal medicine， which possesses the effects of promoting blood circulation， relieving swelling and pain， and dispelling wind and dampness. Modern pharmacological studies have shown that T. wilfordii multiglucoside exhibit anti-inflammatory and immunomodulatory effects， inhibit mesangial cell proliferation， protect podocytes， ameliorate endothelial cell injury， and regulate gut microbiota disturbances. Triptolide also possesses anti-inflammatory and immunomodulatory properties， suppresses mesangial cell proliferation， and protects podocytes. Celastrol demonstrates anti- inflammatory and immunomodulatory functions as well as the ability to improve endothelial cell damage. Through these mechanisms， T. wilfordii and its active components can play a role in alleviating clinical symptoms and delaying disease progression in the treatment of IgAN. Future research should focus on in-depth analysis and mechanistic investigation of these active ingredients， promote high-quality clinical studies， systematically evaluate the synergistic effects among them， and emphasize strategies for reducing toxicity and enhancing efficacy， thereby providing more comprehensive and reliable evidence-based foundations for the clinical treatment of IgAN.
